Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 290,588,832
  • Shares Outstanding, K 2,532,806
  • Annual Sales, $ 60,115 M
  • Annual Income, $ 365,000 K
  • 60-Month Beta 0.39
  • Price/Sales 4.84
  • Price/Cash Flow 38.01
  • Price/Book 6.71
Trade MRK with:

Options Overview Details

View History
  • Implied Volatility 18.98% ( +1.44%)
  • Historical Volatility 14.89%
  • IV Percentile 46%
  • IV Rank 31.76%
  • IV High 27.33% on 07/26/24
  • IV Low 15.09% on 05/17/24
  • Put/Call Vol Ratio 2.02
  • Today's Volume 44,061
  • Volume Avg (30-Day) 25,993
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 340,556
  • Open Int (30-Day) 386,561

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 1.77
  • Number of Estimates 8
  • High Estimate 2.11
  • Low Estimate 1.54
  • Prior Year 2.13
  • Growth Rate Est. (year over year) -16.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
112.41 +0.60%
on 09/09/24
120.30 -5.99%
on 09/06/24
-3.18 (-2.74%)
since 08/26/24
3-Month
110.72 +2.14%
on 08/07/24
132.29 -14.51%
on 06/27/24
-18.41 (-14.00%)
since 06/26/24
52-Week
99.14 +14.07%
on 10/19/23
134.63 -16.00%
on 06/25/24
+7.70 (+7.31%)
since 09/26/23

Most Recent Stories

More News
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal

AstraZeneca AZN and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan (Dato-DXd), failed to achieve statistical significance in the final overall survival...

AZN : 78.18 (+0.83%)
MRK : 113.09 (-1.43%)
GILD : 83.04 (+1.01%)
PFE : 28.97 (+0.14%)
Company News for Sep 24, 2024

Shares of the rate-sensitive Tesla, Inc. TSLA jumped 4.9% on positive expectations from the Fed November meet.Shares of Domino's Pizza, Inc. DPZ gained 1.5% on discretionaries becoming one of the biggest...

APO : 125.50 (+0.78%)
TSLA : 254.22 (-1.09%)
INTC : 23.92 (+1.61%)
MRK : 113.09 (-1.43%)
DPZ : 432.35 (+1.51%)
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer

AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the regulatory filing seeking approval for its ovarian cancer drug Elahere (mirvetuximab...

AZN : 78.18 (+0.83%)
MRK : 113.09 (-1.43%)
ABBV : 191.90 (+0.33%)
PFE : 28.97 (+0.14%)
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs

This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS Kisqali for early breast cancer, Merck’s MRK Keytruda for malignant pleural...

AZN : 78.18 (+0.83%)
JNJ : 161.39 (+0.49%)
MRK : 113.09 (-1.43%)
LLY : 909.32 (-1.65%)
NVS : 115.61 (-0.70%)
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END

ONCY : 0.8976 (-0.23%)
MRK : 113.09 (-1.43%)
NVS : 115.61 (-0.70%)
ONC.TO : 1.22 (-0.81%)
GLMD : 7.33 (+3.39%)
PFE : 28.97 (+0.14%)
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

ONCY : 0.8976 (-0.23%)
MRK : 113.09 (-1.43%)
NVS : 115.61 (-0.70%)
ONC.TO : 1.22 (-0.81%)
GLMD : 7.33 (+3.39%)
PFE : 28.97 (+0.14%)
Is It Too Late to Buy ServiceNow Stock?

The stock is up nearly 60% since the beginning of the year.

STLA : 15.64 (+2.56%)
NOW : 884.86 (-0.58%)
MRK : 113.09 (-1.43%)
IT : 516.47 (+1.05%)
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer...

AZN : 78.18 (+0.83%)
PFE : 28.97 (+0.14%)
MRK : 113.09 (-1.43%)
LLY : 909.32 (-1.65%)
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.

There's a lot of hope for ivonescimab, but are investors being a bit too bullish?

MRK : 113.09 (-1.43%)
SMMT : 22.81 (+0.75%)
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.

MRK : 113.09 (-1.43%)
PFE : 28.97 (+0.14%)
MRNA : 63.93 (+0.46%)
VRTX : 463.15 (+0.30%)
VKTX : 62.32 (-1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 114.82
2nd Resistance Point 114.41
1st Resistance Point 113.75
Last Price 113.09
1st Support Level 112.68
2nd Support Level 112.27
3rd Support Level 111.61

See More

52-Week High 134.63
Fibonacci 61.8% 121.07
Fibonacci 50% 116.89
Last Price 113.09
Fibonacci 38.2% 112.70
52-Week Low 99.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar